Concurrence of Macular Edema with Cataract Extraction

Irvine-Gass Macular Edema Responding to the Combination of Oral Mineralocorticoid-Receptor Antagonist With Dexamethasone Drops

“…Inflammation, vitreous traction, and choroidal blood-flow changes and instability have been advanced. [13][14][15] Oral mineralocorticoid receptor (MR) antagonists are efficient in reducing subretinal and intraretinal fluid in central serous chorioretinopathy (CSCR), [16][17][18][19] in which vascular choroidal changes are recognized. Hypothesizing that both inflammation and vascular choroidal changes contribute to Irvine-Gass syndrome, we employed the combination of oral MR antagonists with dexamethasone drops in three cases of recalcitrant long-lasting Irvine-Gass.…”

“…However, the exact mechanisms of chronic postoperative ME and its persistence are unclear. Inflammation, vitreous traction, and choroidal blood-flow changes and instability have been advanced 13–15…”

Irvine-Gass Macular Edema Responding to the Combination of Oral Mineralocorticoid-Receptor Antagonist With Dexamethasone Drops

“…Inflammation, vitreous traction, and choroidal blood-flow changes and instability have been advanced. [13][14][15] Oral mineralocorticoid receptor (MR) antagonists are efficient in reducing subretinal and intraretinal fluid in central serous chorioretinopathy (CSCR), [16][17][18][19] in which vascular choroidal changes are recognized. Hypothesizing that both inflammation and vascular choroidal changes contribute to Irvine-Gass syndrome, we employed the combination of oral MR antagonists with dexamethasone drops in three cases of recalcitrant long-lasting Irvine-Gass.…”

“…However, the exact mechanisms of chronic postoperative ME and its persistence are unclear. Inflammation, vitreous traction, and choroidal blood-flow changes and instability have been advanced 13–15…”

Irvine-Gass Macular Edema Responding to the Combination of Oral Mineralocorticoid-Receptor Antagonist With Dexamethasone Drops

“…Inflammation, vitreous traction, and choroidal blood-flow changes and instability have been advanced. [13][14][15] Oral mineralocorticoid receptor (MR) antagonists are efficient in reducing subretinal and intraretinal fluid in central serous chorioretinopathy (CSCR), [16][17][18][19] in which vascular choroidal changes are recognized. Hypothesizing that both inflammation and vascular choroidal changes contribute to Irvine-Gass syndrome, we employed the combination of oral MR antagonists with dexamethasone drops in three cases of recalcitrant long-lasting Irvine-Gass.…”

“…However, the exact mechanisms of chronic postoperative ME and its persistence are unclear. Inflammation, vitreous traction, and choroidal blood-flow changes and instability have been advanced 13–15…”

Irvine-Gass Macular Edema Responding to the Combination of Oral Mineralocorticoid-Receptor Antagonist With Dexamethasone Drops

“…Inflammation, vitreous traction, and choroidal blood-flow changes and instability have been advanced. [13][14][15] Oral mineralocorticoid receptor (MR) antagonists are efficient in reducing subretinal and intraretinal fluid in central serous chorioretinopathy (CSCR), [16][17][18][19] in which vascular choroidal changes are recognized. Hypothesizing that both inflammation and vascular choroidal changes contribute to Irvine-Gass syndrome, we employed the combination of oral MR antagonists with dexamethasone drops in three cases of recalcitrant long-lasting Irvine-Gass.…”

“…However, the exact mechanisms of chronic postoperative ME and its persistence are unclear. Inflammation, vitreous traction, and choroidal blood-flow changes and instability have been advanced 13–15…”